Our ophthalmic study is a signature specialty of West China-Frontier PharmaTech. Our ophthalmologists collaborate

extensively with the ophthalmology department of the West China Hospital. Our lab has 4 well experienced study directors and 3 senior specialists who have conducted pre-clinic studies on ophthalmic medication or intraocular implantable biomaterials for over 10 years.

The lab has state-of-the-art instruments: Retinal camera and color photograph imaging system, fluorescein fundus

angiography, laser photocoagulator, electro-physiological diagnostic systems, optical coherence tomography (OCT),

ophthalmotonometer etc.

So far, the lab has conducted pre-clinic studies on 22 ophthalmic medications (macromolecular, small molecule or nucleic acid), of which 1 has come to market, 2 have obtained clinical approval, 9 have finished pre-clinical safety study and filed for clinical approval, 8 are under-going pre-clinical safety studies. Indications include age-related macular degeneration (AMD), uveitis and vitreum adhesion.

• Laser-Induced Choroidal Neovascularization (CNV) Model in Rhesus Monkeys
• Hyperbaric Oxygen-induced Fundus Neovascularization Model in Mice
• Uveitis Model in Rabbit/Monkey
• Vitreous Adhesion Model in Pig

• Indirect Ophthalmoscopy: macula, optic nerve head, retina, and retinal vessels
• Slit Lamp Examination: conjunctiva, cornea, anterior chamber, iris, lens etc.
• Anterior Segment and Fundus Color Photography
• Intraocular Pressure Examination
• SOptical Coherence Tomography
• Fluorescein Fundus Angiography
• Electroretinography

• Ocular Histopathology